Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line sunitinib plus FOLFIRI for rectal cancer with synchronous metastases (SUREMETS)
2008-005959-19Phase 2Terminated
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib and FOLFIRI in rectal cancer and colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Started Mar 2009; status: terminated.
02
Drugs
sunitinibFOLFIRI
03
Conditions
rectal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-005959-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005959-19.